Dimitris Kikidakis

[Georgios Pappas @GeorgiosPappas6]

«Την πληροφορία πρέπει να την αναζητήσεις μόνος σου. Να ψάξεις τις δημοσιεύσεις, τις επίσημες πηγές, τα δεδομένα. Δεν είναι εύκολη η επιστήμη. Πρέπει να το εξηγήσουμε στους νέους ερευνητές. Είναι εργώδες πράγμα...» Υπόχρεος στον @UrbanRat7 για το άρθρο: https://t.co/tdwkR1h46W

[Adam B. Weiner, MD @Adam_Weiner535]

🚨 PROTEUS: perioperative apalutamide moves into high-risk localized #prostatecancer

Just out in @NEJM

🧬 2109 men w/ high-risk localized or locally advanced PCa randomized to ADT + apalutamide vs ADT + placebo around radical prostatectomy.

🎯 Both stated primary endpoints met.

⚠️ But the trial deserves nuance. Thread 🧵

#ASCO26 @ASCO @PCF_Science

[NEJM @NEJM]

Presented at #ASCO26:

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://t.co/xwLWBZYRzq

@ASCO

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

📐 HR 0.68 = a 32% relative risk reduction in recurrence at any given moment during follow-up.

That sounds like a large benefit.
But the absolute numbers tell a different story:

BCG alone: 81.6% disease-free at 2 years
BCG + durvalumab: 86.5% disease-free at 2 years

Absolute difference: ~5%

Since BCG already works well, a big relative reduction maps to a modest absolute gain. @MaxKates @UrogerliMD @JoshMeeks

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

FDA approves durvalumab in combination with BCG for high-risk non-muscle invasive #bladdercancer

@IBCG_BladderCA @DrFelixGuerrero @joanfundi @tompowles1 @AndreaNecchi @JoshMeeks #ASCO26

[Oncology Brothers @OncBrothers]

Durvalumab now @US_FDA ✅ for Non-Muscle Invasive Bladder cancer based off #POTOMAC: PhIII, BCG + Durvalumab vs. BCG alone in BCG naive HR-NMIBC:

- DFS waiting maturity (HR: 0.68)
- 3yr mDFS 82% vs 77%
- MedOncs will now see HR-NMIBC

#gusm #OncTwitter

[UroToday.com @urotoday]

Final results of a phase II trial of BCG and intravesical gemcitabine for patients with BCG-exposed high-grade #NMIBC. Presented by @WaldoGMed @MSKCancerCenter. #AUA26 written coverage by @zklaassen_md @GACancerCenter > https://t.co/zls9GzgDlh @AmerUrological

[UroToday.com @urotoday]

Advanced #ProstateCancer - First-line #mCRPC/APMR: How do I select the best treatment for my patient? Presentation by @KristineLacuna @MSKCancerCenter. #AUA26 written coverage by @zklaassen_md @GACancerCenter > https://t.co/HXeVYlME8o @AmerUrological

[Zach Klaassen @zklaassen_md]

A treatment intensification algorithm for mHSPC as of May 2026 - @jackiebrown_MD
#AUA26 International Prostate Forum

@urotoday

[Zach Klaassen @zklaassen_md]

#AUA26 International Prostate Forum

@KristineLacuna beautifully explaining to us urologists how to think about 1L mCRPC treatment based on:
-Previous ADT + ARPI
-No previous ADT + APRI
-Other/special sitations

@urotoday

[Sea Bass @Sea_Bass_J]

καλή η άσκηση, ακόμα καλύτερη ίσως η πρωινή άσκηση!

[Dimitris Kikidakis @dkikidakis]

@pharmaki500mg Βλαμμένος κοσμος

[Snoopy @snoopyb047]

May the fourth be with you! Happy Star Wars day

[The Obama Foundation @ObamaFoundation]

May the Fourth be with YOU, from the Obama Presidential Center.

Opening June 19. @BarackObama @MarkHamill

[Culture Crave 🍿 @CultureCrave]

Happy Star Wars Day

[Eleni Varvitsioti @Elbarbie]

Η απάντηση μας στον κ. Τσίπρα για την άρνηση του να συμμετάχει στο ντοκιμαντέρ "Στο Χιλιοστό" https://t.co/IdKmpJGm4e

[Dimitris Kikidakis @dkikidakis]

@eelha0 @korina_p Γεροβασιλείου 🙌🏼🙌🏼🙌🏼🍷🍷

[Harrison Ford @HarrisonFordLA]

May the fourth be with you

[UroToday.com @urotoday]

Targeted #ProstateCancer screening in BRCA1 or BRCA2 pathogenic germline variant carriers detects clinically relevant disease: Results after 5 rounds of PSA screening (The IMPACT Study). Presentation by Rosalind Eeles, PhD, FRCP, FRCR @ICR_London. #APCCC26 written coverage by @zklaassen_md @GACancerCenter > https://t.co/jRaoUlYw4L @APCCC_Lugano